Why Partner with AH?

AH has its own research and development programme. Building on the successful clinical effects seen in IBS for Bif 35624, AH scientists have identified putative components from the organism and other probiotic strains, which in themselves may have therapeutic benefit. These will be progressed as candidate therapeutics in the inflammation and infection disease areas.

AH has a research agreement with the Alimentary Pharmabiotic Centre (APC), an industry academe research initiative set up by the Irish Government in 2003. This centre received a grant of €16.5m from government for the period 2003 – 2008 and it is expected to generate novel biopharmaceutical candidates, which AH intends to licence for clinical and commercial development. This association is an important aspect of AH’s pipeline research strategy.

AH operates a successful patent strategy to protect its intellectual property. Patent applications have been filed and funded to nationalisation phase in a significant number of key Patent Cooperation Treaty (PCT) countries including in Europe, the Americas and Asia.

AH has product production knowledge and extensive contacts with leading manufacturing, formulation, packaging and distribution companies to facilitate future supply & commercialisation.